Genfit SA logo
Genfit SA GNFT

Annual report 2024
added 03-21-2026

report update icon

Genfit SA EBITDA 2011-2026 | GNFT

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA Genfit SA

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- - - 31.8 M -82.9 M -57.8 M -69.5 M -56.7 M -33.4 M -17.2 M -17 M -9.94 M -7 M -6.99 M

All numbers in EUR currency

Indicator range from annual reports

Maximum Minimum Average
31.8 M -82.9 M -29.7 M

References

  1. Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Biotechnology industry

Issuer EBITDA Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
-508 M - 2.43 % $ 254 M germanyGermany
ARCA biopharma ARCA biopharma
ABIO
-88.1 M - 1052.0 % $ 415 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
-8.67 M - 5.93 % $ 314 M canadaCanada
Albireo Pharma Albireo Pharma
ALBO
-123 M - -0.23 % $ 916 M usaUSA
I-Mab I-Mab
IMAB
13.8 M - - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
3.11 B - - $ 40.3 B usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
-65 M - 10.36 % $ 9.8 M usaUSA
Biophytis SA Biophytis SA
BPTS
-26.8 M - -13.47 % $ 169 M franceFrance
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
-452 M $ 215.54 -1.16 % $ 5 B danmarkDanmark
Midatech Pharma plc Midatech Pharma plc
MTP
-7 M - -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
-8.18 M - -1.52 % $ 24.7 M usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
172 M $ 19.23 - $ 899 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
-16.2 M - - $ 26.5 M usaUSA
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
-85.1 M $ 8.18 -2.97 % $ 109 M usaUSA
CytomX Therapeutics CytomX Therapeutics
CTMX
-21.2 M $ 4.24 -4.93 % $ 585 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
-9.76 M - -10.17 % $ 12.2 K usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
-233 M - -24.86 % $ 820 K usaUSA
Acasti Pharma Acasti Pharma
ACST
-16.7 M - 4.01 % $ 150 M canadaCanada
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
220 M - - - russiaRussia
Eton Pharmaceuticals Eton Pharmaceuticals
ETON
3.2 M $ 22.97 -3.53 % $ 618 M usaUSA
CollPlant Biotechnologies Ltd. CollPlant Biotechnologies Ltd.
CLGN
-16.2 M $ 0.71 17.15 % $ 8.13 M israelIsrael
Fortress Biotech Fortress Biotech
FBIO
-109 M $ 2.92 -2.01 % $ 60.7 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
-136 M - - $ 86.2 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
-24.5 M - 2.71 % $ 14 M usaUSA
Advaxis Advaxis
ADXS
-35.9 M - -9.65 % $ 45.9 M usaUSA
Exelixis Exelixis
EXEL
901 M $ 41.57 0.39 % $ 11.3 B usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
-11.3 M - -52.27 % $ 4.45 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
-234 M $ 1.32 -5.71 % $ 337 M britainBritain
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
-37.3 M - - $ 7.46 M israelIsrael
ChemoCentryx ChemoCentryx
CCXI
-127 M - - $ 3.74 B usaUSA
Genmab A/S Genmab A/S
GMAB
6.57 B $ 25.81 0.51 % $ 16.6 B danmarkDanmark
Aytu BioScience Aytu BioScience
AYTU
-2.45 M $ 2.65 0.76 % $ 16.6 M usaUSA
Grifols, S.A. Grifols, S.A.
GRFS
595 M $ 7.6 -1.17 % $ 6.83 B spainSpain
Halozyme Therapeutics Halozyme Therapeutics
HALO
480 M $ 62.04 -1.3 % $ 7.43 B usaUSA
Atreca Atreca
BCEL
5.46 M - -11.76 % $ 5.79 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
37.3 M - -4.8 % $ 255 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
-242 M - - $ 1.01 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
-412 M - - $ 867 M germanyGermany
BeiGene, Ltd. BeiGene, Ltd.
BGNE
589 M - 0.49 % $ 251 B cayman-islandsCayman-islands
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
-22.4 M - -74.18 % $ 955 K usaUSA
Immatics N.V. Immatics N.V.
IMTX
-86.3 M $ 9.2 -3.26 % $ 579 M germanyGermany
Incyte Corporation Incyte Corporation
INCY
1.61 B $ 90.62 0.19 % $ 17.7 B usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
-285 M - - $ 3.67 B usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
-37.8 M $ 4.31 -2.49 % $ 826 M canadaCanada
Akouos Akouos
AKUS
-84.3 M - 0.23 % $ 488 M usaUSA
Ionis Pharmaceuticals Ionis Pharmaceuticals
IONS
-204 M $ 69.68 -1.57 % $ 11.1 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
-11.4 M - 1.93 % $ 17.4 M usaUSA
Allakos Allakos
ALLK
-190 M - - $ 28.6 M usaUSA
Brickell Biotech Brickell Biotech
BBI
-6.32 M - -5.38 % $ 6.06 M usaUSA